Trials / Completed
CompletedNCT04970667
Flupentixol and Melitracen Tablets in the Treatment of Emotional Disorder
Clinical Study of Flupentixol and Melitracen Tablets in the Treatment of Non Random Emotional Disorder
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Peking University Third Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of Flupentixol melitracen tablets in the treatment of different types of non random emotional disorders
Detailed description
Involuntary emotional expression disorder (ieed) is a kind of disorder of emotion control. Its main clinical feature is frequent short and violent uncontrollable crying and (or) laughing, which is different from mood disorder and self emotional expression. The mixture of Flupentixol and melitracen is used for antidepressant. Melitracen is a tricyclic antidepressant, while Flupentixol is a neurodepressant in structure, but its dose in Deanxit has antidepressant properties. The active components of Deanxit are Flupentixol dihydrochloride (Flupentixol) and melitracen (melitracen). Flupentixol is a thiazolyl (thioanthracene) antipsychotic, and melitracen is a tricyclic antidepressant. Low dose Flupentixol (0.5mg-3mg) has antidepressant and antianxiety effects, while melitracen has antidepressant effect. The mixture of the two components is used to treat mild to moderate mental disorders. The purpose of this study was to evaluate the efficacy and safety of Flupentixol melitracen tablets in the treatment of different types of non random emotional disorders.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Flupentixol melitracen tablets | Patients were treated with Flupentixol and melitracen tablets for 12 weeks |
Timeline
- Start date
- 2018-01-01
- Primary completion
- 2020-01-31
- Completion
- 2020-04-30
- First posted
- 2021-07-21
- Last updated
- 2021-07-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04970667. Inclusion in this directory is not an endorsement.